- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | Surrozen secures patent for tissue repair technology | 1 | Investing.com | ||
| 14.05. | Surrozen, Inc.: Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway | 144 | GlobeNewswire (Europe) | Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating... ► Artikel lesen | |
| 09.05. | Surrozen GAAP EPS of -$7.43 misses by $5.65, revenue of $0.98M | 1 | Seeking Alpha | ||
| 09.05. | Surrozen, Inc./DE - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.05. | Surrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update | 805 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively... ► Artikel lesen | |
| 09.05. | Surrozen, Inc./DE - 8-K, Current Report | 1 | SEC Filings | ||
| 31.03. | Surrozen, Inc./DE - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 31.03. | Surrozen, Inc.: Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates | 46 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the... ► Artikel lesen | |
| SURROZEN Aktie jetzt für 0€ handeln | |||||
| 31.03. | Surrozen, Inc./DE - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | Surrozen, Inc./DE - 8-K, Current Report | 1 | SEC Filings | ||
| 24.03. | Surrozen, Inc./DE - 8-K, Current Report | 2 | SEC Filings | ||
| 24.03. | Surrozen, Inc.: Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases | 1 | GlobeNewswire (USA) | ||
| 24.03. | Surrozen shifts focus to eye disease treatments, secures $175M funding | 1 | Investing.com | ||
| 24.03. | Surrozen drops sole clinical-stage drug over weak hepatitis data, pivots to eye disease | - | FierceBiotech | ||
| 06.11.24 | Surrozen, Inc.: Surrozen Provides Third Quarter 2024 Financial Results and Business Update | 377 | GlobeNewswire (Europe) | Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 Nominated novel portfolio... ► Artikel lesen | |
| 12.08.24 | Surrozen, Inc.: Surrozen Provides Second Quarter 2024 Financial Results and Business Update | 984 | GlobeNewswire (Europe) | Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL Published study that demonstrated application... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,70 | -0,60 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Evotec steigt in Mega-Forschungsprojekt ein - Hoffnungsschimmer für Millionen Nierenpatienten | Evotec SE treibt seine Strategie in der personalisierten Medizin weiter voran und verkündet den Beitritt zum renommierten NURTuRE-AKI-Konsortium. Mit diesem Schritt zielt das MDAX- und TecDAX-notierte... ► Artikel lesen | |
| CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
| AMGEN | 237,00 | +0,11 % | Amgen-Aktie mit Kursverlusten (237,1233 €) | An der US-amerikanischen Börse notiert die Aktie von Amgen derzeit etwas leichter. Der jüngste Kurs betrug 277,19 US-Dollar. An der Börse liegt die Aktie von Amgen zur Stunde im Minus. Das Wertpapier... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,470 | +2,17 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,450 | +2,27 % | Biotech-Pick: Warum sie diese Aktie unbedingt auf dem Zettel haben sollten! | ||
| IBIO | 0,745 | +4,93 % | Pharos iBio Receives IND Approval for PHI-501 Phase 1 Trial | ||
| ARROWHEAD PHARMACEUTICALS | 13,400 | -2,40 % | Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results | PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting... ► Artikel lesen | |
| COHERUS ONCOLOGY | 0,643 | +1,42 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,494 | -1,27 % | Voyager Therapeutics, Inc.: Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication | LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced... ► Artikel lesen | |
| OPGEN | 2,600 | 0,00 % | OPGEN INC - 8-K, Current Report | ||
| MEREO BIOPHARMA | 2,330 | +2,19 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights | Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 15,634 | +5,08 % | Swedish Orphan Biovitrum AB: Sobi and Apellis: Aspaveli/Empaveli Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases | STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating... ► Artikel lesen | |
| BENITEC BIOPHARMA | 11,260 | -8,83 % | Benitec Biopharma Inc.: Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update | -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular... ► Artikel lesen | |
| CYBIN | 7,100 | +0,71 % | Neural Therapeutics: Innovative Meskalin-Therapien für psychische Gesundheit |
SURROZEN INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +12,61 % bei einem Aktienkurs von 9,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SURROZEN INC finden Sie auf Wallstreet Online.